ELAN · Elanco Animal Health Inc
$23.56
-0.94 (-3.84%)
At close · Aug 20
Market Cap
$12.16B
Shares
499.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.56
Open$24.21
Day$23.38–24.37
52W close$17.35–26.84
Avg vol 30d7.2M
Short int36.0M · 7.2% float · 7.3d
Short vol42%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
−4%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
65%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−11%
trailing
YTD return
+4%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $24 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +80 funds added
Insider flow
Accumulating
Net +$537.1K over 90 days · 0% sells
Short interest
Rising
7.21% of float · ▲ +0.5% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
517 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
55%
expanding
EPS growth
−169%
Y/Y
Free cash flow
$284.0M
Balance sheet
$3.8B
net debt
Quant / Vol
risk profile
Volatility
43%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Full Year 2026
Innovation revenue target
Initiated
$1.25B
Adjusted EBITDA
Non-GAAP
Initiated
$1.01B – $1.04B
2026 full year
Revenue growth (organic, constant currency)
Initiated
6% – 7%
Adjusted gross margin
Non-GAAP
Initiated
55.2% – 55.6%
Revenue tailwind from foreign exchange rates vs prior year
Initiated
$60M
2026 Third Quarter
Operating expenses growth (constant currency)
Initiated
10%
Revenue growth (organic, constant currency)
Initiated
5% – 7%
Prior guidance
period ended
· from the 8-K filed Feb 24, 2026
Revenue
· 2026 First Quarter
$1.28B – $1.31B
Adjusted EBITDA
· 2026 First Quarter
$290M – $310M
Adjusted Earnings per Share
· 2026 First Quarter
$0.33 – $0.36
Guided vs delivered
· last 3 settled
Revenue
second quarter
guided $1.15B – $1.17B
$1.18B
Beat +2.3%
Revenue
full year 2024
guided $4.45B – $4.54B
$4.44B
Miss −1.2%
Revenue
first quarter 2024
guided $1.16B – $1.19B
$1.21B
Beat +2.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
−4%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
65%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $25 › 200d $24 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +80 funds added
Insider flow
Accumulating
Net +$537.1K over 90 days · 0% sells
Short interest
Rising
7.21% of float · ▲ +0.5% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
517 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17
Now $24 · 65%
Range high $27
vs 200-day avg 0%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $0.75 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $622M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 22.9% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted gross margin percentage non-GAAP | 57.5% | Six Months Ended June 30, 2026 | — |
| Adjusted gross profit non-GAAP | $1.57B | Six Months Ended June 30, 2026 | — |
| Adjusted net income non-GAAP | $378M | Six Months Ended June 30, 2026 | — |
| Net leverage ratio non-GAAP | 3.1 | As of June 30, 2026 | — |
| Organic constant currency revenue growth non-GAAP | 8% | Q2 2026 | — |
|
|
|||
| Trailing twelve month adjusted EBITDA non-GAAP | $1.01B | As of June 30, 2026 | — |
| Innovation revenue | $892M | full year | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELAN
this stock
Elanco Animal Health Inc
|
$12.16B | +4.1% | +6.2% | — | 7.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELAN | +4.7% | -4.9% | -10.8% | -10.7% | +4.1% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +6.6% | -8.2% | -21.9% | -12.7% | -7.7% |
Key facts
CIK
1739104
CUSIP
28414H103
13F (30d)
474 filings
446 filers
Visit website
Investor relations